anti-PD-L1/TGFbetaRII fusion protein 6MW3511

{
  "id": "MLC-T-ONC-011031",
  "term": "anti-PD-L1/TGFbetaRII fusion protein 6MW3511",
  "field": "Oncology and biomedicine",
  "definition": "A bifunctional fusion protein composed of a humanized anti-programmed death ligand 1 (PD-L1) nanobody fused to a mutant form of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein 6MW3511, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the anti-PD-L1 nanobody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor immune responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis. The TGFbetaRII moiety is modified to enhance the stability of the agent.",
  "synonyms": [
    "anti-PD-L1 nanobody/TGFbetaRII mutant fusion protein 6MW3511",
    "anti-PD-L1/TGFbetaRII bifunctional fusion protein 6MW3511"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-tgfbetarii-fusion-protein-6mw3511/"
}